On Monday, California biotech industry executives met to discuss the challenges faced by small biotech start-ups in today’s deal-making environment.
The roundtable, moderated by William Looney, the editor in chief of Pharmaceutical Executive, and hosted by Joseph Panetta, the executive director of Southern California’s life science trade association, BIOCOM, focused on understanding what models work for drug development, partnering and commercialization in the wake of a shifting economic climate.
William Looney, Pharmaceutical Executive (Source James Dickens)
Joe Panetta, BIOCOM (Source James Dickens)
The event was organized by Russo Partners and included panelists from biotech companies, big pharma and venture capital in California whose collective insight shed light on the ever-changing world of innovation and big pharma partnering.
Kleanthis Xanthopoulos, Regulus Therapeutics (Source James Dickens)
Jay Lichter, Avalon Ventures (Source James Dickens)
Bob Baltera, Amira Pharmaceuticals (Source James Dickens)
The topics of discussion included the factors that contribute to a biotech start-up’s success, such as a clinically relevant pipeline and cash liquidity, as well as the regulatory and financial pressures of today’s marketplace. Panelists were asked to describe their own strategies for negotiating big pharma partnerships and where they see opportunity in 2011 and beyond.
Kathy Bowdish, Anaphore (Source James Dickens)
Bill Newell, Sutro Biopharma (Source James Dickens)
A summary of the discussion and the conclusions drawn from the roundtable will be featured in the January issue of Pharmaceutical Executive.
The roundtable participants:
Bob Baltera, President and CEO, Amira Pharmaceuticals
Kathy Bowdish, President and CEO, Anaphore
Jay Lichter, Managing Director, Avalon Ventures
Margi McLoughlin, Senior Director R&D Business Development, Pfizer Inc.
Bill Newell, CEO, Sutro Biopharma
Kleanthis Xanthopoulos, President and CEO, Regulus Therapeutics
Joseph Panetta, Executive Director, BIOCOM [host]
William Looney, Editor in Chief, Pharmaceutical Executive [moderator]
Ian Stone, Russo Partners [observer]
Heidi Chokeir, Russo Partners [observer]